H. Lundbeck A/S, a global leader in brain health, has announced a strategic agreement with the Danish Centre for AI Innovation (DCAI), the organization responsible for operating Gefion, Denmark’s AI supercomputer. Lundbeck is one of the first pharmaceutical companies to utilize Gefion’s computational power to advance drug discovery and development in the field of neurological and psychiatric disorders.
Revolutionizing Brain Health with AI
Brain disorders affect approximately half of the global population, severely impairing their quality of life. Despite scientific advances, there remain significant unmet needs in brain health, with many patients having limited treatment options. By harnessing the extraordinary computational power of Gefion, Lundbeck aims to accelerate the discovery of next-generation treatments for neurological and psychiatric conditions.
The use of AI-driven insights into molecule discovery and drug optimization is expected to enhance Lundbeck’s ability to develop innovative therapies. With Gefion’s AI capabilities, Lundbeck will explore novel avenues in molecule discovery, working on improving medicines for established drug targets and unlocking new emerging drug targets.
Advancing Drug Discovery and Treatment Development
Lundbeck’s Senior Vice President & Head of Research, Tarek Samad, emphasized the strategic importance of this collaboration:
“We are excited to be among the pioneers utilizing Gefion’s AI supercomputing power. The advanced computational capabilities of Gefion offer the potential to push the boundaries in treating brain diseases and enable us to develop treatments at an unprecedented pace.”
Transforming Brain Disease Research through AI
This agreement marks a key milestone in AI-powered research at Lundbeck. Claus Thomsen, Senior Vice President of Global IT at Lundbeck, highlighted the role of AI in the company’s research strategy:
“Working with DCAI and gaining access to Gefion is an important step in transforming brain disease research through AI. It provides our researchers with cutting-edge software and tools to leverage the rapid development of AI-driven analysis and large-scale simulations, aligning with our strategy to harness AI’s potential for patient benefit.”
A Collaborative Milestone for the Future of AI in Pharmaceuticals
Nadia Carlsten, CEO of the Danish Centre for AI Innovation (DCAI), expressed her enthusiasm for the collaboration:
“It’s an exciting milestone for us to work with an innovator like Lundbeck. Since launching Gefion, it’s rewarding to see its power aiding Lundbeck’s scientists in uncovering new treatment pathways more efficiently. This partnership has the potential to significantly accelerate the timeline for delivering impactful neurological therapies to patients.”
The Future of AI in Pharma and Healthcare Innovation
As AI continues to revolutionize industries, Gefion stands at the forefront of transforming pharmaceutical and biotech innovation. The agreement between DCAI and Lundbeck underscores the potential of AI supercomputing to address some of the world’s most pressing healthcare challenges.
“Together with Lundbeck, we can showcase how AI supercomputing can be a game-changer in the fight against neurological disorders,” said Nadia Carlsten.
The collaboration between Lundbeck and DCAI represents a major step forward in utilizing AI to address the brain health crisis. With Gefion’s advanced capabilities, Lundbeck is set to lead the charge in transforming neurological research and drug discovery, helping unlock new treatment options for patients with neurological and psychiatric conditions. As AI reshapes the pharmaceutical industry, this partnership promises to deliver breakthrough innovations in brain health.
